Congress
$1,001–$15,000
Traded Jul 17 · disclosed 49 days laterLate
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
KVUE · NYSE · Personal Care Products
No longer listed: the shares stopped trading on Nov 3, 2026, usually after a takeover, a merger or a move off the exchange. The price and the charts stop there; the filings stay.
Kenvue (KVUE) · oqro.io/stocks/KVUE · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Kenvue was filed in the last 90 days. The latest on record was on Dec 15, 2025.
Since 2023, Kenvue insiders reported 4 open-market purchases and 3 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2025.
No open-market sale by an insider of Kenvue (KVUE) was filed with the SEC in the last 90 days.
Yes. Members of Congress disclosed 15 trades in Kenvue (KVUE) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Rep. Gilbert Ray Cisneros Jr. (CA31), Rep. Kevin Hern (OK01), Sen. Alan Armstrong and 2 other members.
Kenvue's next results are expected on Feb 15, 2027, before the market opens. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$19.31−0.25 (−1.28%)
Close of Oct 30, 2026, vs Oct 29 · end-of-day, not a live quote
+35.6% (+$5.07) from Oct 30, 2025 to Oct 30, 2026 · adjusted daily closes
Adjusted close went from $14.24 on Oct 30, 2025 to $19.31 on Oct 30, 2026 (+35.6%). Disclosed in this range: 4 insider trades, 0 pre-arranged insider sales, 12 Congress trades, and 88 13F position changes for 3 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Personal Care Products company based in Skillman, New Jersey.
Last 12 months
Not enough history
Market value
$37.1B
Short interest: 52.4M shares sold short (2.7% of shares outstanding), −6.0% vs the previous count, 2.5 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$3.89B
+3.2% vs the same quarter a year earlier
Free cash flow, last 12 months
$2.34B
This quarter $620M, a year earlier $196M
Net debt
—
Debt —, cash $1.04B, at Sep 27, 2026
Net income, last 12 months
$1.69B
Operating profit covers interest 6.4x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 30, 2026.
Revenue, fiscal 2025
$15.1B
−2.1% vs the year before
Net income, fiscal 2025
$1.47B
As reported in the annual filing
Shares outstanding
1.92B
As of Oct 26, 2026
In fiscal 2025 the company spent $197M buying back its own shares and $1.58B on dividends. Cash actually paid, from its cash-flow statement.
Congress
Traded Jul 17 · disclosed 49 days laterLate
2 different filers disclosed KVUE within 90 days.
Fund moves
52 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
36 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
52 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
21 tracked managers disclosed the same change for Q1 2026. From a 13F filed Aug 14, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Kenvue reported 4 open-market purchases and 3 sales since 2023; purchases in 2 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $747K2×2 trades |
| 2025 | $111M2×2 trades | $394K1×1 trade |
| 2023 | $654K2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Notice of delisting or failure to meet listing rules
8-K on sec.govTop officer leaving
“(the “Company”) announced that Amit Banati, the current Chief Financial Officer, will step down from his role effective May 12, 2026.”
8-K on sec.govTop officer leaving
“(the “Company”) that he will step down from his position as Chief Financial Officer, effective May 12, 2026, to pursue an opportunity to serve as the chief executive officer of another company.”
8-K on sec.govTop officer leaving
“…employees as participants who Kenvue has historically treated as covered by the plan, including Carlton Lawson, Group President, EMEA & Latin America and (iii) providing that the A&R Severance Plan may not be terminated or amended in a manner adverse to the participants for the two-year period following the closing of the Mergers.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
A securities lawsuit naming the company as a defendant was filed on Oct 9, 2023 in the U.S. District Court, D. New Jersey. A filing is an allegation, not a finding.
HAMMOND v. KENVUE INC., 3:23-cv-20998A securities lawsuit naming the company as a defendant was filed on Oct 9, 2023 in the U.S. District Court, D. New Jersey. A filing is an allegation, not a finding.
HAMMOND v. KENVUE INC., 1:23-cv-20998Federal civil cases with nature of suit 850 (securities) filed in the last 3 years where the company is the first named defendant, from court records on CourtListener (Free Law Project). 1 case in that period is closed and not listed. Coverage of court records is not complete, and shareholder derivative suits are not included.
Last results
Oct 30, 2026
Within the 30 days after it, until Nov 29, 2026
Next results, expected
Feb 15, 2027
before the market opens; the date can move until the company confirms it
Purchases after results
Not enough history
From Kenvue's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Kenvue's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
FMR LLC
13G · passive · Up from 7% · 157M shares · filed Aug 6, 2026
Vanguard Capital Management
13G · passive · Crossed 5% · 144M shares · filed Apr 30, 2026
Recent moves
FMR LLC raised its stake to 8.2% from 7% · Schedule 13G, 2026
FMR LLC went above 5%, with 7% · Schedule 13G, 2026
Vanguard Capital Management went above 5%, with 7.5% · Schedule 13G, 2026
The Vanguard Group fell below 5% (0%) · Schedule 13G, 2026
T. Rowe Price Associates, Inc. fell below 5% (1%) · Schedule 13G, 2026
FMR LLC fell below 5% (4.7%) · Schedule 13G, 2025
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Against the S&P 500 over the year
Fiscal year Dec 30, 2024 to Dec 28, 2025, from the annual report filed Feb 20, 2026. Read the filing
−2.3% on the year before ($6.53B)
−1.2% on the year before ($4.69B)
−3.0% on the year before ($4.24B)
Since Oct 29, 2025, KVUE is up 34.9% and the index fund is up 9.9%: 25 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much KVUE moves
Beta 0.1 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 238 trading days (1 = in step with it).
−4.2% on the year before ($7.58B)
+4.6% on the year before ($3.56B)
−6.7% on the year before ($2.97B)
+1.9% on the year before ($1.34B)
The company also reports United States ($6.46B), which group lines above and are not added again.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 14,000 words.
At Kenvue, our purpose is to realize the extraordinary power of everyday care. As a global leader at the intersection of healthcare and consumer goods, we are the world’s largest pure-play consumer health company by revenue with $15.1 billion in Net sales in the fiscal year 2025. By combining the power of science with meaningful consumer insights and our digital strategy, we empower consumers to live healthier lives every day. Built on more than a century of heritage and trusted by generations, our differentiated portfolio of iconic brands—including Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena®, Nicorette®, Tylenol®, and Zyrtec®—is backed by science and recommended by healthcare professionals, which further reinforces our consumers’ connections to our brands.
And 26 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 20, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Congress
Funds and stakes
Contracts, lobbying and filings
Short sale volume: 32.4% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 37.2%. FINRA daily files, to Oct 30, 2026.
Fails to deliver: 92K shares (about $1.79M) were not delivered on time for settlement on Oct 28, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 38.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (9.1% on ATS, 29.2% with other brokers), below its 26-week average of 51.0%. Weeks of Oct 5 to Oct 30, 2026.
Company reports, price and press
Who holds it
Deals
Things to keep in mind
Records
Largest ATS: INTELLIGENT CROSS LLC (18.2%), UBS ATS (9.1%), ONECHRONOS (8.7%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Latest annual report filed Feb 20, 2026, compared with the one filed Feb 24, 2025. Read the filing
And 8 more headings in the filing.
The information required by this item is incorporated herein by reference to Note 17, “Commitments and Contingencies,” to the Consolidated Financial Statements included herein.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 20, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.